...Inc. (NASDAQ:AGLE) while Hamburger was VP, regulatory affairs and quality assurance at Tarveda Therapeutics Inc. BiomX...
...was EVP commercialization and outcomes at ICON plc (NASDAQ:ICLR). Jonathan Block, Associate Editor Gilead Sciences Inc. Checkmate Pharmaceuticals Inc. BiomX Inc. Anixa...

...DISEASE CATEGORY: Neurology INDICATION: Amyotrophic lateral sclerosis (ALS) Co-founders and collaborators of DayTwo Ltd. and BiomX...

...Weizmann professors and co-founders of microbiome-based nutrition company DayTwo Ltd. Elinav is also co-founder of BiomX...

...suggesting modulation of the gut microbiome could treat ALS. Elinav is also a co-founder of BiomX...
...21; PARP - Poly(ADP-ribose) polymerase; TYK2 - tyrosine kinase 2 Hongjiang Li and Sandi Wong, Staff Writers BMS-986165 BiomX Inc. Cytokinetics...

...papillomatosis and DNA-Encoded Bi-specific T Cell Engagers (dBTEs) programs. BiomX planning listing after reverse merger BiomX...
...Inc., Takeda Ventures and Seventure Partners. Elizabeth S. Eaton, Staff Writer, and Erin McCallister, Senior Editor BX001 Relebactam/imipenem/cilastatin FDC BiomX Inc. Inovio...

...drug discovery, with an initial focus in oncology. BiomX licenses bacterial targets for phage therapies BiomX...
...targets, including specific strains of Klebsiella pneumoniae , from JSR Corp. (Tokyo, Japan) against which BiomX...
...and Mary Romeo, Staff Writers AR101, arc001, peanut allergy oral immunotherapy (oit) Keytruda, pembrolizumab (MK-3475, lambrolizumab) Viaskin Peanut (DBV-712) BiomX Inc. DBV...

...compromised environment, and anaerobic. It makes sense bacteria can survive and thrive there.” Jonathan Solomon, BiomX...
...anaerobic. It makes sense bacteria can survive and thrive there,” said Jonathan Solomon, CEO of BiomX...
...bystander strains, which could make it more difficult to pinpoint translationally relevant strains. Solomon said BiomX...

...I/II testing for infectious disease, gastrointestinal disease and cancer. Jonathan Solomon, CEO of phage company BiomX...
...disease (IBD) the team found “is somewhat speculative at this point and requires additional investigation.” BiomX...
...chronic inflammatory disease. Targets: IFNγ - Interferon γ; TLR9 - Toll-like receptor 9 Chris Lieu, Staff Writer BiomX Inc. Crohn's...

...S.A.S. (Paris, France); LNC Therapeutics (Bordeaux, France); TargEDys (Rouen, France); A-Mansia Biotech S.A. (Louvain-la-Neuve, Belgium); BiomX...

...has backed at least two other companies through the fund this year; on Feb. 20, BiomX...
...Bioscience S.A. (Paris, France) raised €32 million ($36.3 million) in a series D round (see “BiomX...